glp 1 fda approved for weight loss Approves Lilly's Foundayo: The New GLP-1 Pill What's New in Obesity Treatment?

Companies such as Hengrui, Hansoh Pharmaceutical and others are now advancing their own obesity assets, not only for the domestic market but with ambitions beyond China

Through statistical analyses, the researchers estimate that there was a 4.28 times greater risk of developing the condition in patients prescribed semaglutide, according to the study, published in JAMA Ophthalmology

Epigenetic network in immunometabolic disease

doi: 10.2174/138161211796196954

Despite intensive glycemia control having proven clinical benefits for several outcomes, the residual risk of cardiovascular (CV) death has remained a significant unmet need in patients with T2DM